大型语言模型增强药物重新定位 通过长链思维提取知识:开发和评估研究
Hongyu Kang1,2, Jiao Li2, Li Hou2
1School of Medical Technology, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing, 100081, China, 86 13693067129.
JMIR medical informatics
|October 7, 2025
概括
这项研究引入了一种用于药物重新定位知识提取的新框架,提高了大型语言模型的准确性. 开发的系统提供了一个专门的体和一个轻量级的模型,用于高效的药物发现.
科学领域:
- 生物医学信息学 生物医学信息学
- 人工智能在药物发现中的作用
- 自然语言处理自然语言处理.
背景情况:
- 药物重新定位加速治疗发现,但面临复杂,分散的生物医学数据的挑战.
- 传统的信息提取方法在准确性和通用性方面扎.
- 大型语言模型 (LLM) 显示出潜力,但与幻觉和可解释性存在问题.
研究的目的:
- 引入药物重新定位知识提取的长思维链 (LCoDR-KE),这是一个轻量级的框架,以提高LLM的准确性和适应性.
- 加强用于药物重新定位应用的结构化生物医学知识的提取.
主要方法:
- 开发了一个具有11个实体和18个关系的域特定方案.
- 利用思维链提示工程来对10,000个PubMed摘要进行自动注释.
- 从1000个经过专家验证的摘要中策划了一个专门的药物重新定位集体.
- 结合Qwen2.5-7B-Instruct的监督微调与强化学习和双奖励机制.
主要成果:
- LCoDR-KE实现了81.46%的实体F1和69.04%的三重F1,超过了传统模型.
- 该框架与较大的LLM竞争,证明了轻量级方法的有效性.
- 废弃性研究证实了监督微调和强化学习的显著贡献.
结论:
- LCoDR-KE增强了LLM在药物重新定位方面的领域特定适应能力.
- 该框架提供了一个开源的库和一个可扩展的,可解释的解决方案,用于生物医学知识提取.
- 这种方法支持药物发现和知识推理,具有更广泛应用的潜力.
相关概念视频
Drug Discovery: Overview
11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K
Drug Nomenclature
3.2K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.2K
Drug Biotransformation: Overview
3.6K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.6K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Pharmacokinetic Models: Overview
1.9K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.9K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K


